Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Frequently asked questions
What sector does Nuvation Bio Inc (NUVB) operate in?
Nuvation Bio Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Nuvation Bio Inc (NUVB) current stock price?
As of the latest data, Nuvation Bio Inc stock price is $4.51, with a previous close of $4.57. Nuvation Bio Inc lost -$0.06 in the last trading session, representing a -1.31% loss.
What is Nuvation Bio Inc (NUVB) current market capitalization?
Nuvation Bio Inc market cap is approximately 1.58 billion.
What is Nuvation Bio Inc (NUVB) Earnings Per Share (EPS)?
The trailing EPS is -$0.44, and the forward EPS is -$0.02.
What is Nuvation Bio Inc (NUVB) EBITDA?
Nuvation Bio Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -55.55 million.
Does Nuvation Bio Inc (NUVB) pay dividends?
No. Nuvation Bio Inc does not pay a dividend.
How did Nuvation Bio Inc (NUVB) perform in its most recent earnings report?
In the last report (June 30, 2026), Nuvation Bio Inc posted an EPS surprise of 0% and a revenue surprise of 15.33%.
When is Nuvation Bio Inc (NUVB) next earnings report?
Nuvation Bio Inc is expected to release its next earnings report on September 30, 2026.
What is Nuvation Bio Inc (NUVB) beta (volatility) score?
Nuvation Bio Inc has a beta of 1.526, suggesting it is more volatile than the market.
